Sanofi Delves Further into Protein Degrader Therapies with US$2.33 B Kymera Deal

By Ashish Tripathi & Michelle Liu

Pharma Deals Review: Vol 2020 Issue 9 (Table of Contents)

Published: 8 Sep-2020

DOI: 10.3833/pdr.v2020.i9.2560     ISSN: 1756-7874

Section: Licensing



Continuing its interest in targeted protein degradation space, Sanofi has entered into a multi-programme strategic collaboration with Kymera Therapeutics to develop and commercialise IRAK4 degraders in inflammation and immunology indications...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details